Loading company…
Symphogen develops antibody therapies for oncology and immune oncology.
Founded in 2000, Symphogen is a Denmark-based biotechnology company developing antibody therapies for cancer and immune oncology. Its discovery platform supports research into antibodies targeting complex tumor environments. Kirsten Drejer is CEO. The company has collaborated with pharmaceutical companies and entered licensing agreements for its technologies. EW Healthcare Partners acquired Symphogen.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in